Costly drugs and Medicare finances

Medicare may be on a collision course with the biopharma industry's prices for innovative medicines. A Center for Retirement Research report on the financial implications for Medicare of Alzheimer's drug Aduhelm is featured in a front-page story in today's Boston Globe, with comments by CRR Director Alicia Munnell.